Streetbeat News

Revenues

SVT

Servotronics (SVT) reported a decline in Q3 earnings year-over-year due to higher overhead costs and a less favorable product mix, despite a 7.3% increase in revenues.

Portfolio Pulse from

November 12, 2024 | 6:45 pm

ARMK

Aramark's Q4 earnings met expectations with record revenues and profitability, leading to an 11% dividend increase.

Portfolio Pulse from

November 12, 2024 | 6:30 pm

NICE

NICE is expected to report strong third-quarter earnings, driven by its innovative portfolio, high demand for customer experience solutions, and increasing cloud revenues, despite a challenging macroeconomic environment.

Portfolio Pulse from

November 12, 2024 | 6:30 pm

AZN

AstraZeneca has raised its full-year sales outlook due to strong demand for its cancer and rare-disease drugs. The company also announced a $3.5 billion investment in its U.S. business by 2026.

Portfolio Pulse from

November 12, 2024 | 6:30 pm

TSN

Tyson Foods (TSN) shares surged after the company reported better-than-expected profit and sales, driven by higher beef and chicken prices.

Portfolio Pulse from

November 12, 2024 | 6:30 pm

BA

Boeing forecasts that air cargo traffic will double by 2043, driven by emerging markets, with an average annual growth of 4%.

Portfolio Pulse from

November 12, 2024 | 6:15 pm

BKNG

Booking Holdings' stock has surged following strong Q3 results, with growth accelerating to 9% year-over-year. The company is benefiting from a European recovery and increased air ticket sales. A planned restructuring aims to further improve margins.

Portfolio Pulse from

November 12, 2024 | 6:15 pm

ZTS

Zoetis is a key player in the rapidly growing pet industry, which is projected to reach $500 billion by 2032. The company focuses on both companion and production animal health, investing in research and AI to drive innovation and profitability.

Portfolio Pulse from

November 12, 2024 | 6:15 pm

SPT

Kuehn Law is investigating Sprout Social, Inc. for potential breaches of fiduciary duties by its officers and directors. Allegations include misrepresentation of sales growth, integration challenges with the acquisition of Tagger, and misleading statements about the company's prospects.

Portfolio Pulse from

November 12, 2024 | 6:00 pm

MIRM

Mirum Pharmaceuticals (MIRM) reported third-quarter 2024 earnings and revenues that exceeded estimates. The company also raised its revenue guidance for 2024.

Portfolio Pulse from

November 12, 2024 | 6:00 pm